BioSpace News Archive

Pathologic Clearance: 100% Tumor Clearance (Complete Response) in One Patient, Greater than 90% (Near Complete Response) in Second Patient, Greater than 50% (Partial Response) in Third Patient Pathologic Results Assessed at Approximately 5 Weeks Safety Monitoring Committee Issues Favorable Review of Safety Data at the Maximum Dose

November 3, 2025

·

5 min read

Press Releases

Theralase(R) Demonstrates Effectiveness of X-Ray-Activated Drug

November 3, 2025

·

1 min read

Press Releases

CellCentric to Host Investor Event and Present Dose Optimization Data from Phase 2 Study of Inobrodib for Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting

- Preliminary results confirm earlier findings that inobrodib in combination with pomalidomide + dexamethasone (InoPd) for multiple myeloma has promising clinical activity and a tolerable safety profile in a heavily pretreated population - - The Company will host a live investor event on December 7, at 8:00 p.m. ET in Orlando following the poster presentation -

November 3, 2025

·

4 min read

Brain shaped maze. Conceptual image of science and medicine. 3D illustration.

Neuroscience

Roche Piles $55M Into Blood-Brain Barrier Tech With Manifold

Manifold will use its tissue-targeting shuttle technology to help Roche develop new therapeutics for diseases of the central nervous system.

November 3, 2025

·

1 min read

·

Annalee Armstrong